Nasdaq

Exact Sciences price target raised to $70 from $60 at Evercore ISI

Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...
Hosted on MSN

Exact Sciences price target raised to $85 from $65 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Exact Sciences (EXAS) to $85 from $65 and keeps a Buy rating on the shares. The firm would be a buyer of Exact Sciences. With the Freenome deal in place ...

T. Rowe Price Health Sciences Fund

The T. Rowe Price Health Sciences Fund falls into Morningstar’s health category. Funds in this category generally buy stocks in the medical and health care industries. According ...
Hosted on MSN

Exact Sciences (EXAS) Price Target Increased by 18.76% to 84.57

) has been revised to $84.57 / share. This is an increase of 18.76% from the prior estimate of $71.21 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...
Nasdaq

Exact Sciences (EXAS) Price Target Increased by 18.76% to 84.57

The average one-year price target for Exact Sciences (NasdaqCM:EXAS) has been revised to $84.57 / share. This is an increase of 18.76% from the prior estimate of $71.21 dated November 7, 2025. The ...